COLITIS, ULCERATIVE

This study tested a drug called ustekinumab in 112 children with moderate-to-severe ulcerative colitis, a condition causing inflammation in the colon. The goal was to see if the drug could reduce symptoms like diarrhea and bleeding and help the colon heal. Children first received…

This study tested a medicine called vedolizumab in 121 children with moderate to severe ulcerative colitis, a condition causing inflammation and pain in the gut. The goal was to see if the drug could help children achieve remission, meaning their symptoms improve and tests show l…

This completed Phase 2b trial tested an oral tablet called JNJ-77242113 against placebo in 252 adults with moderate-to-severe ulcerative colitis. The goal was to see if the drug could reduce symptoms and inflammation better than a dummy pill. Researchers measured clinical respons…

This phase 2b trial tested a new drug called TEV-48574 (duvakitug) in 290 adults with moderate to severe ulcerative colitis or Crohn's disease. The study aimed to see if the drug could help patients achieve clinical remission (for UC) or an endoscopic response (for CD) after 14 w…

This study tested an experimental pill called MORF-057 in 39 adults with moderate to severe ulcerative colitis. The drug aims to reduce gut inflammation by blocking a specific protein. Researchers measured changes in colon tissue health and symptom scores after 12 weeks of treatm…

This study monitored 688 people in South Korea with ulcerative colitis, Crohn's disease, or pouchitis who were treated with Kynteles (vedolizumab) as part of their normal care. The main goal was to track side effects, and researchers also looked at how many patients saw symptom i…

This study looked at the long-term safety of a drug called spesolimab in adults with moderate to severe ulcerative colitis who had already finished earlier trials. Researchers tracked side effects and checked if patients achieved remission over about 6.5 years. The goal was to se…

This study tested two doses of a daily pill called ozanimod in 198 Japanese adults with moderate to severe ulcerative colitis. The goal was to see if it could reduce symptoms and inflammation better than a placebo. The trial also checked long-term safety. Ozanimod works by calmin…

This study tested a new drug called spesolimab in 98 adults with moderate-to-severe ulcerative colitis who did not get better with other biologic treatments. The goal was to see if the drug could safely reduce symptoms and help the colon heal. The trial was completed and looked a…

This phase 2 study tested whether adding spesolimab to standard TNF inhibitor therapy could help heal the gut lining in people with mild-to-moderate ulcerative colitis. Twenty-two adults who still had active disease despite TNF inhibitor treatment received spesolimab or a placebo…

This phase 2 trial tested a drug called spesolimab in 8 adults with moderate to severe ulcerative colitis. The main goal was to understand how the drug works in the body, while also checking for safety and any signs of improvement. Participants received the drug for 12 weeks, and…

This study looked at physical fitness in 100 children and teens (ages 10-17) with chronic inflammatory bowel disease (Crohn's disease, ulcerative colitis, or unclassified colitis) and compared them to healthy kids of the same age, weight, and sex. Researchers measured cardiorespi…

This study observed 92 adults with Crohn's disease or ulcerative colitis who were receiving vedolizumab either as an intravenous infusion or a subcutaneous injection. Researchers tracked treatment patterns, such as whether patients stayed on their current form or switched, over 1…